CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $504,964 | -19.1% | 11,125 | 0.0% | 0.01% | -23.1% |
| Q2 2023 | $624,558 | +24.1% | 11,125 | 0.0% | 0.01% | +30.0% |
| Q1 2023 | $503,184 | +102.1% | 11,125 | +81.6% | 0.01% | +150.0% |
| Q4 2022 | $248,981 | -37.8% | 6,125 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $400,000 | +7.5% | 6,125 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $372,000 | -3.1% | 6,125 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $384,000 | -17.2% | 6,125 | 0.0% | 0.01% | -20.0% |
| Q4 2021 | $464,000 | -32.4% | 6,125 | 0.0% | 0.01% | -37.5% |
| Q3 2021 | $686,000 | -30.8% | 6,125 | 0.0% | 0.02% | -20.0% |
| Q2 2021 | $992,000 | +33.0% | 6,125 | 0.0% | 0.02% | +17.6% |
| Q1 2021 | $746,000 | -20.5% | 6,125 | 0.0% | 0.02% | -45.2% |
| Q4 2020 | $938,000 | +83.2% | 6,125 | 0.0% | 0.03% | +47.6% |
| Q3 2020 | $512,000 | +13.8% | 6,125 | 0.0% | 0.02% | +31.2% |
| Q2 2020 | $450,000 | +107.4% | 6,125 | +19.5% | 0.02% | +60.0% |
| Q1 2020 | $217,000 | – | 5,125 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |